Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Rimsza LM. PMBL: flying under the immune radar. Blood . 2019;134(10):788-789.

Blood (2020) 135 (6): 458.

https://doi.org/10.1182/blood.2019004712

Published: 2020

Journal Articles

PMBL: flying under the immune radar

Lisa M. Rimsza

Blood (2019) 134 (10): 788–789.

https://doi.org/10.1182/blood.2019002493

Published: 2019

Journal Articles

Prevalence of RNA Editing Events Affecting Coding Regions in Pediatric Leukemia

Ji Wen, PhD, Michael Rusch, Michael Edmonson, PhD, Charles Mullighan, MBBS, MSc, MD, Tanja A. Gruber, MD PhD, David W Ellison, MD, Jinghui Zhang, PhD

Blood (2016) 128 (22): 3928.

https://doi.org/10.1182/blood.V128.22.3928.3928

Published: 2016

Journal Articles

Neonatal GATA1 mutant clones under the radar

Jeffrey W. Taub

Blood (2013) 122 (24): 3851–3853.

https://doi.org/10.1182/blood-2013-10-527598

Published: 2013

Journal Articles

Assessment Of Minimal Residual Disease In Acute Myeloblastic Leukemia In Multiparameter Flow Cytometry

Blood (2013) 122 (21): 2613.

https://doi.org/10.1182/blood.V122.21.2613.2613

Published: 2013

Journal Articles

Anaphylaxis Associated with Administration of Repeated Courses of Rasburicase: A Research On Adverse Drug Events and Reports (RADAR) Project

Katherine C Allen, PharmD, Amanda H Champlain, MD, Jonathan Cotliar, MD, Steven M. Belknap, MD, Dennis P. West, PhD, Jayesh Mehta, MD, Steven Trifilio

Blood (2012) 120 (21): 1351.

https://doi.org/10.1182/blood.V120.21.1351.1351

Published: 2012

Journal Articles

Hemophagocytic Lymphohistiocytosis: Truly On the Rise or Simply On the Radar?.

Kelly Ann Bodio, MD, Meghan Campo, MD, Jon E. Arnason, MD

Blood (2012) 120 (21): 2151.

https://doi.org/10.1182/blood.V120.21.2151.2151

Published: 2012

Journal Articles

“Getting to go” for FDA Approvals for the Treatment of Hematologic Versus Solid Tumor Malignancies: A Report from the Research on Adverse Drug Events and Reports (RADAR) Project

Elizabeth A Richey, BA, Veena Shankaran, MD, Steven Hirschfeld, MD, PhD, Steven M Trifilio, RPh, June McKoy, MD, MPH, Kenneth R Carson, MD, Beatrice J Edwards, MD, FACP, Thanh Ha Luu, BA, Narissa Nonzee, BS, A. Oliver Sartor, MD, Charles L. Bennett, MD, PhD, MPP

Blood (2008) 112 (11): 2402.

https://doi.org/10.1182/blood.V112.11.2402.2402

Published: 2008

Journal Articles

Thalidomide (thal), Lenalidomide (len), and Dexamethasone (dex)-Associated Venous Thromboembolism (VTE) and Reported VTE Rates Pre- and Post-FDA Approval: Optimal Prophylaxis Strategies Are Still Unclear

Monica Boen, BA, June McKoy, MD, MPH, Dennis West, Beatrice Edwards, Jayesh Mehta, Seema Singhal, Charles L. Bennett, MD, PhD, MPP

Blood (2008) 112 (11): 2403.

https://doi.org/10.1182/blood.V112.11.2403.2403

Published: 2008

Journal Articles

Novel Dissemination Efforts for Hematology-Related Serious Adverse Drug Reactions (sADRs): Findings from the Research on Adverse Drug Events and Reports Project (RADAR)

Cara C Tigue, BA, Dennis P West, PhD, Dennis W Raisch, PhD, RPh, Beatrice J Edwards, MD, FACP, Simone N Boyle, BA, Athena T Samaras, BA, Paul Bennett, Charles L. Bennett, MD, PhD, MPP

Blood (2008) 112 (11): 4662.

https://doi.org/10.1182/blood.V112.11.4662.4662

Published: 2008

Journal Articles

Progressive Multifocal Leukoencephalopathy Associated with Rituximab Treatment of B-Cell Lymphoproliferative Disorders: A Report of 29 Cases from the RADAR Project.

Kenneth R. Carson, MD, Andrew M. Evens, DO, Steven T. Rosen, MD, Jane N. Winter, MD, Leo I. Gordon, MD, Numa Gottardi-Littell, MD, David Green, MD, Charles L. Bennett, MD

Blood (2007) 110 (11): 370.

https://doi.org/10.1182/blood.V110.11.370.370

Published: 2007

Journal Articles

Evaluating Mortality with Erythropoietic Stimulating Agents (ESAs) in the Nephrology Setting: The Distinction between Evaluating Trials That Measure Survival as a Primary or Secondary Efficacy Endpoint Versus a Safety Endpoint.

Sara E. Barnato, MD, Charles L. Bennett, MD PhD MPP, Kathleen Elverman, Dennis P. West, PhD, Mark Courtney, MD

Blood (2007) 110 (11): 962.

https://doi.org/10.1182/blood.V110.11.962.962

Published: 2007

Journal Articles

Rapid Identification of Hematology-Associated Serious Adverse Drug Reactions (sADRS) with Small Datasets: Findings from the Research on Adverse Drug Events and Reports (RADAR) Project.

Nina Undevia, MD MPH, Cara C. Tigue, BA, Dennis P. West, PhD, June M. McKoy, MD MPH JD, Beatrice J. Edwards, MD, David A. Dorr, MD MS, Dennis W. Raisch, RPh PhD, Charles L. Bennett, MD, PhD, MPP

Blood (2007) 110 (11): 3339.

https://doi.org/10.1182/blood.V110.11.3339.3339

Published: 2007

Journal Articles

Inadvertent Intrathecal Administration of Vincristine.

Praveena Basetty, MD, Charlie G. Buffie, BA, Jennifer Lagman, RN, Cara C. Tigue, BA, Neal Dandade, BA, Charles L. Bennett, MD PhD MPP

Blood (2006) 108 (11): 3327.

https://doi.org/10.1182/blood.V108.11.3327.3327

Published: 2006

Journal Articles

RADAR Update on Thalidomide (Thal)- and Lenalidomide (Len)-Associated Venous Thromboembolism (VTE): Safety Concerns Persist for Multiple Myeloma (MM) Despite FDA Approvals in This Setting.

Charles L. Bennett, MD, PhD, MPP, Zehra Hussain, Mark Courtney, MD MPH, Paul Yarnold, PhD, Dennis Raisch, PhD, June M. McKoy, MD JD MPH

Blood (2006) 108 (11): 3310.

https://doi.org/10.1182/blood.V108.11.3310.3310

Published: 2006

Journal Articles

2006 RADAR Report Card on Conversion Rates from Accelerated FDA Approval to Regular FDA Approval for Drugs Used To Treat Hematologic Malignancies: Policy Changes Continue To Be Needed.

Andrew J. Lurie, BGS, Mark V. Mai, Martin S. Tallman, MD, June McCoy, MD JD MPH, Charles L. Bennett, MD PhD MPP

Blood (2006) 108 (11): 3318.

https://doi.org/10.1182/blood.V108.11.3318.3318

Published: 2006

Journal Articles

A Multi-Institution Retrospective Case Report Analysis of Emergence of Breakthrough Zygomycoses in Patients on Prior Voriconazole Therapy.

Steven M. Trifilio, RPh, Lakshmi Balasubramanian, MD, MS, Jayesh Mehta, MD, Martin S. Tallman, MD, LeAnne Kennedy, PharmD, Charles L. Bennett, MD, MPP, Dimitrios P. Kontoyiannis, MD

Blood (2005) 106 (11): 3227.

https://doi.org/10.1182/blood.V106.11.3227.3227

Published: 2005

Journal Articles

2005 Update on Accelerated FDA Approval of Drugs Used To Treat Hematologic Malignancies from the Research on Adverse Drug-Events and Reports (RADAR): Rate of Regular Approval Conversion Remains Low.

Charles L. Bennett, MD, PhD, MPP, Jessica A. Zagory, BA, June M. McKoy, MD, MPH, JD, Kathryn R. McCaffrey, BA, E. Allison Lyons, BA, Steven Belknap, MD

Blood (2005) 106 (11): 289.

https://doi.org/10.1182/blood.V106.11.289.289

Published: 2005

Journal Articles

Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project

Blood (2005) 106 (10): 3343–3347.

https://doi.org/10.1182/blood-2005-02-0508

Published: 2005

Journal Articles

FDA Policies Should Be Amended To Allow Pharmaceutical Manufacturers To Disseminate Information Regarding Potentially Fatal Toxicities That Occur with Off-Label Use of Oncology Agents: A Policy Recommendation Based on Review of Thalidomide-Associated Thromboembolism Cases by the RADAR Project.

Andrew M. Evens, DO, Martin S. Tallman, MD, Seema Singhal, MD, June M. McKoy, MD, JD, E. Allison Lyons, BA, Dennis W. Raisch, PhD, Paul R. Yarnold, PhD, Hau Kwaan, MD, Timothy M. Kuzel, MD, Jayesh Mehta, MD, Charles L. Bennett, MD, PhD

Blood (2004) 104 (11): 265.

https://doi.org/10.1182/blood.V104.11.265.265

Published: 2004

NARROW

Rimsza LM. PMBL: flying under the immune radar. Blood . 2019;134(10):788-789.

PMBL: flying under the immune radar

Prevalence of RNA Editing Events Affecting Coding Regions in Pediatric Leukemia

Neonatal GATA1 mutant clones under the radar

Assessment Of Minimal Residual Disease In Acute Myeloblastic Leukemia In Multiparameter Flow Cytometry

Anaphylaxis Associated with Administration of Repeated Courses of Rasburicase: A Research On Adverse Drug Events and Reports (RADAR) Project

Hemophagocytic Lymphohistiocytosis: Truly On the Rise or Simply On the Radar?.

“Getting to go” for FDA Approvals for the Treatment of Hematologic Versus Solid Tumor Malignancies: A Report from the Research on Adverse Drug Events and Reports (RADAR) Project

Thalidomide (thal), Lenalidomide (len), and Dexamethasone (dex)-Associated Venous Thromboembolism (VTE) and Reported VTE Rates Pre- and Post-FDA Approval: Optimal Prophylaxis Strategies Are Still Unclear

Novel Dissemination Efforts for Hematology-Related Serious Adverse Drug Reactions (sADRs): Findings from the Research on Adverse Drug Events and Reports Project (RADAR)

Progressive Multifocal Leukoencephalopathy Associated with Rituximab Treatment of B-Cell Lymphoproliferative Disorders: A Report of 29 Cases from the RADAR Project.

Evaluating Mortality with Erythropoietic Stimulating Agents (ESAs) in the Nephrology Setting: The Distinction between Evaluating Trials That Measure Survival as a Primary or Secondary Efficacy Endpoint Versus a Safety Endpoint.

Rapid Identification of Hematology-Associated Serious Adverse Drug Reactions (sADRS) with Small Datasets: Findings from the Research on Adverse Drug Events and Reports (RADAR) Project.

Inadvertent Intrathecal Administration of Vincristine.

RADAR Update on Thalidomide (Thal)- and Lenalidomide (Len)-Associated Venous Thromboembolism (VTE): Safety Concerns Persist for Multiple Myeloma (MM) Despite FDA Approvals in This Setting.

2006 RADAR Report Card on Conversion Rates from Accelerated FDA Approval to Regular FDA Approval for Drugs Used To Treat Hematologic Malignancies: Policy Changes Continue To Be Needed.

A Multi-Institution Retrospective Case Report Analysis of Emergence of Breakthrough Zygomycoses in Patients on Prior Voriconazole Therapy.

2005 Update on Accelerated FDA Approval of Drugs Used To Treat Hematologic Malignancies from the Research on Adverse Drug-Events and Reports (RADAR): Rate of Regular Approval Conversion Remains Low.

Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project

FDA Policies Should Be Amended To Allow Pharmaceutical Manufacturers To Disseminate Information Regarding Potentially Fatal Toxicities That Occur with Off-Label Use of Oncology Agents: A Policy Recommendation Based on Review of Thalidomide-Associated Thromboembolism Cases by the RADAR Project.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only